Early experience with baroreflex activation therapy from a vascular surgery perspective

• DOI: 10.1016/j.jvscit.2024.101464
• Publication Date: 2024-02-24T17:05:53Z
• Authors: Christopher Yu Chow; Christopher Montoya; Matthew Sussman; Stefan Kenel-Pierre; Omaida Caridad Ve...; Luanda Grazette; Tony Shao
• Keywords: Medical record

Baroreflex activation therapy (BAT) is an emerging device-based treatment for patients with heart failure a reduced ejection fraction refractory to maximally tolerated goal-directed medical therapy. Currently, there sparse literature on the critical role that vascular surgeons serve in delivery of this novel This single-institution series describes creation BAT program and elaborates function multidisciplinary team. The preoperative evaluation, perioperative care, postoperative course receiving from March 2022 August 2023 were retrospectively analyzed. Eleven evaluated by dedicated cardiologist eligibility assessed surgeon technical feasibility. Of 11 patients, 7 men (63.6%). median age was 60.5 years (range, 44-73 years). No patient (0.00%) had existing carotid artery disease, one (9.1%) undergone previous neck radiation All (100%) cardiac implantable electronic device, implantation performed same side as device two (18.1%). Four (36.4%) required hospital admission optimization before surgery. length surgery 82 minutes 58-113 minutes), stay after 1 day 0-6 days). major adverse neurologic or cardiovascular events, cranial nerve injuries, complications requiring reintervention, failure-related mortality at 6 months occurred. Three (27.3%) experienced extraneous stimulations, which affected tolerability. Within implantation, no significant improvements observed several disease burden markers compared implantation. Our early results demonstrate safe procedure rare complications. Vascular play important More data are needed understand whether beneficial